國立虎尾科技大學 |

Retinal Degenerative Diseases = Mechanisms and Experimental Therapy /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Retinal Degenerative Diseases/ edited by Catherine Bowes Rickman, Christian Grimm, Robert E. Anderson, John D. Ash, Matthew M. LaVail, Joe G. Hollyfield.
Reminder of title:	Mechanisms and Experimental Therapy /
other author:	Bowes Rickman, Catherine.
Description:	XVI, 596 p. 132 illus., 86 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Immunology. -
Online resource:	https://doi.org/10.1007/978-3-030-27378-1
ISBN:	9783030273781

Retinal Degenerative Diseases = Mechanisms and Experimental Therapy /
Retinal Degenerative DiseasesMechanisms and Experimental Therapy /[electronic resource] :edited by Catherine Bowes Rickman, Christian Grimm, Robert E. Anderson, John D. Ash, Matthew M. LaVail, Joe G. Hollyfield. - 1st ed. 2019. - XVI, 596 p. 132 illus., 86 illus. in color.online resource. - Advances in Experimental Medicine and Biology,11850065-2598 ;. - Advances in Experimental Medicine and Biology,889.

This book contains the proceedings of the XVIII International Symposium on Retinal Degeneration (RD2018). A majority of those who spoke and presented posters at the meeting contributed to this volume. The blinding diseases of inherited retinal degenerations have no treatments, and age-related macular degeneration has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 70. The RD Symposium focused on the exciting new developments aimed at understanding these diseases and providing therapies for them. Since most major scientists in the field of retinal degenerations attend the biennial RD Symposia, they are known by most as the “best” and “most important” meetings in the field. The volume presents representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; candidate genes, cloning, mapping and other aspects of molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy. While advances in these areas of retinal degenerations were described, there will be many new topics that either are in their infancy or did not exist at the time of the last RD Symposium, RD2016. These include the role of inflammation and immunity, as well as other basic mechanisms, in age-related macular degeneration, several new aspects of gene therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials. The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS. Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those were reported at the RD2016 meeting and included in the current volume. We anticipate the excitement of those working in the field and those afflicted with retinal degenerations is reflected in the volume. .

ISBN: 9783030273781

Standard No.: 10.1007/978-3-030-27378-1doiSubjects--Topical Terms:

592892
Immunology.

LC Class. No.: QR180-189.5

Dewey Class. No.: 616.079

Retinal Degenerative Diseases = Mechanisms and Experimental Therapy /
LDR:04161nam a22003975i 4500 001 1005468
003 DE-He213
005 20200703170405.0
007 cr nn 008mamaa
008 210106s2019 gw | s |||| 0|eng d
020 $a 9783030273781 $9 978-3-030-27378-1
024 7 $a 10.1007/978-3-030-27378-1 $2 doi
035 $a 978-3-030-27378-1
050 4 $a QR180-189.5
072 7 $a MJCM $2 bicssc
072 7 $a MED044000 $2 bisacsh
072 7 $a MJCM $2 thema
082 0 4 $a 616.079 $2 23
245 1 0 $a Retinal Degenerative Diseases $h [electronic resource] : $b Mechanisms and Experimental Therapy / $c edited by Catherine Bowes Rickman, Christian Grimm, Robert E. Anderson, John D. Ash, Matthew M. LaVail, Joe G. Hollyfield.
250 $a 1st ed. 2019.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2019.
300 $a XVI, 596 p. 132 illus., 86 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Advances in Experimental Medicine and Biology, $x 0065-2598 ; $v 1185
520 $a This book contains the proceedings of the XVIII International Symposium on Retinal Degeneration (RD2018). A majority of those who spoke and presented posters at the meeting contributed to this volume. The blinding diseases of inherited retinal degenerations have no treatments, and age-related macular degeneration has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 70. The RD Symposium focused on the exciting new developments aimed at understanding these diseases and providing therapies for them. Since most major scientists in the field of retinal degenerations attend the biennial RD Symposia, they are known by most as the “best” and “most important” meetings in the field. The volume presents representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; candidate genes, cloning, mapping and other aspects of molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy. While advances in these areas of retinal degenerations were described, there will be many new topics that either are in their infancy or did not exist at the time of the last RD Symposium, RD2016. These include the role of inflammation and immunity, as well as other basic mechanisms, in age-related macular degeneration, several new aspects of gene therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials. The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS. Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those were reported at the RD2016 meeting and included in the current volume. We anticipate the excitement of those working in the field and those afflicted with retinal degenerations is reflected in the volume. .
650 0 $a Immunology. $3 592892
650 0 $a Ophthalmology. $3 644487
650 0 $a Neurosciences. $3 593561
700 1 $a Bowes Rickman, Catherine. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1102041
700 1 $a Grimm, Christian. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 681741
700 1 $a Anderson, Robert E. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 678259
700 1 $a Ash, John D. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1024608
700 1 $a LaVail, Matthew M. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 889172
700 1 $a Hollyfield, Joe G. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 678260
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030273774
776 0 8 $i Printed edition: $z 9783030273798
776 0 8 $i Printed edition: $z 9783030273804
830 0 $a Advances in Experimental Medicine and Biology, $x 0065-2598 ; $v 889 $3 1253792
856 4 0 $u https://doi.org/10.1007/978-3-030-27378-1
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)